Abstract:Anxiety disorders are prevalent and disabling yet understudied from a genetic standpoint, compared with other major psychiatric disorders such as bipolar disorder and schizophrenia. The fact that they are more common, diverse and perceived as embedded in normal life may explain this relative oversight. In addition, as for other psychiatric disorders, there are technical challenges related to the identification and validation of candidate genes and peripheral biomarkers. Human studies, particularly genetic ones, are susceptible to the issue of being underpowered, because of genetic heterogeneity, the effect of variable environmental exposure on gene expression, and difficulty of accrual of large, well phenotyped cohorts. Animal model gene expression studies, in a genetically homogeneous and experimentally tractable setting, can avoid artifacts and provide sensitivity of detection. Subsequent translational integration of the animal model datasets with human genetic and gene expression datasets can ensure cross-validatory power and specificity for illness. We have used a pharmacogenomic mouse model (involving treatments with an anxiogenic drug—yohimbine, and an anti-anxiety drug—diazepam) as a discovery engine for identification of anxiety candidate genes as well as potential blood biomarkers. Gene expression changes in key brain regions for anxiety (prefrontal cortex, amygdala and hippocampus) and blood were analyzed using a convergent functional genomics (CFG) approach, which integrates our new data with published human and animal model data, as a translational strategy of cross-matching and prioritizing findings. Our work identifies top candidate genes (such as FOS, GABBR1, NR4A2, DRD1, ADORA2A, QKI, RGS2, PTGDS, HSPA1B, DYNLL2, CCKBR and DBP), brain–blood biomarkers (such as FOS, QKI and HSPA1B), pathways (such as cAMP signaling) and mechanisms for anxiety disorders—notably signal transduction and reactivity to environment, with a prominent role for the hippocampus. Overall, this work complements our previous similar work (on bipolar mood disorders and schizophrenia) conducted over the last decade. It concludes our programmatic first pass mapping of the genomic landscape of the triad of major psychiatric disorder domains using CFG, and permitted us to uncover the significant genetic overlap between anxiety and these other major psychiatric disorders, notably the under-appreciated overlap with schizophrenia. PDE10A, TAC1 and other genes uncovered by our work provide a molecular basis for the frequently observed clinical co-morbidity and interdependence between anxiety and other major psychiatric disorders, and suggest schizo-anxiety as a possible new nosological domain.

Prioritization and Association Analysis of Murine-Derived Candidate Genes in Anxiety-Spectrum Disorders

Nominating novel proteins for anxiety via integrating human brain proteomes and genome-wide association study

Neurabin in the Anterior Cingulate Cortex Regulates Anxiety-Like Behavior in Adult Mice

Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms

Meta-analyses of genome-wide linkage scans of anxiety-related phenotypes

Identification of novel genomic loci for anxiety symptoms and extensive genetic overlap with psychiatric disorders

Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling

Gene networks associated with conditional fear in mice identified using a systems genetics approach

Genome-wide meta-analysis, functional genomics and integrative analyses implicate new risk genes and therapeutic targets for anxiety disorders

Analysis of common genetic variation of anxiety disorders in essential tremor

Implication of NOTCH1 gene in susceptibility to anxiety and depression among sexual abuse victims

Identification of Novel Rare Variants for Anxiety: an Exome-Wide Association Study in the UK Biobank

GPR26-deficient Mice Display Increased Anxiety- and Depression-Like Behaviors Accompanied by Reduced Phosphorylated Cyclic AMP Responsive Element-Binding Protein Level in Central Amygdala

Inter-α-inhibitor deficiency in the mouse is associated with alterations in anxiety-like behavior, exploration and social approach

Gene Discovery and Biological Insights into Anxiety Disorders from a Multi-Ancestry Genome-wide Association Study of >1.2 Million Participants

Collective interaction effects associated with mammalian behavioral traits reveal genetic factors connecting fear and hemostasis

Expression Pattern of the Cannabinoid Receptor Genes in the Frontal Cortex of Mood Disorder Patients and Mice Selectively Bred for High and Low Fear

Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study

Behavioral characterization of A/J and C57BL/6J mice using a multidimensional test: Association between blood plasma and brain magnesium-ion concentration with anxiety

RNA-seq Co-Expression Network Analysis Reveals Anxiolytic Behavior of Mice with Efnb2 Knockout in Parvalbumin+ Neurons

Translational approaches to anxiety: focus on genetics, fear extinction and brain imaging